Literature DB >> 12764871

[New antimicrobial drugs: an update].

Heinz Burgmann1.   

Abstract

Several procedures such as antimicrobial restriction, microbial monitoring, calculated antimicrobial treatment and the development of new antimicrobials are used to reduce the resistance. The following reviews deals with new substances such as carbapenems, quinolones, ketolides, oxazolidinones, glycylcyclines, echinocandines and azoles.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12764871     DOI： 10.1046/j.1563-258x.2003.03019.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  23 in total

Review 1.  An updated safety profile of moxifloxacin.

Authors:  P B Iannini; L A Mandell
Journal:  J Chemother       Date:  2002-02       Impact factor: 1.714

Review 2.  Voriconazole: in the treatment of invasive aspergillosis.

Authors:  Richard B R Muijsers; Karen L Goa; Lesley J Scott
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Efficacy and safety of telithromycin in community-acquired pneumonia.

Authors:  Dirkie J Van Rensburg; Peter A Matthews; Bruno Leroy
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

4.  Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis.

Authors:  M Aubier; P M Aldons; A Leak; D D McKeith; B Leroy; M Rangaraju; C Bienfait-Beuzon
Journal:  Respir Med       Date:  2002-11       Impact factor: 3.415

5.  Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.

Authors:  Susan C Nicholson; Kevin P High; Samantha Gothelf; C Douglas Webb
Journal:  Diagn Microbiol Infect Dis       Date:  2002-09       Impact factor: 2.803

Review 6.  Novel agents for resistant Gram-positive infections--a review.

Authors:  Jacob Strahilevitz; Ethan Rubinstein
Journal:  Int J Infect Dis       Date:  2002-03       Impact factor: 3.623

Review 7.  Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features.

Authors:  J M Blondeau; G T Hansen
Journal:  Expert Opin Pharmacother       Date:  2001-02       Impact factor: 3.889

Review 8.  IV-to-oral switch therapy for community-acquired pneumonia requiring hospitalization: focus on gatifloxacin.

Authors:  Lorenzo Pelly
Journal:  Adv Ther       Date:  2002 Sep-Oct       Impact factor: 3.845

9.  Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Authors:  Joseph S Solomkin; Albert E Yellin; Ori D Rotstein; Nicolas V Christou; E Patchen Dellinger; Jose M Tellado; Osvaldo Malafaia; Alvaro Fernandez; Kyuran A Choe; Alexandra Carides; Vilas Satishchandran; Hedy Teppler
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

Review 10.  Caspofungin acetate for treatment of invasive fungal infections.

Authors:  Staci A Pacetti; Steven P Gelone
Journal:  Ann Pharmacother       Date:  2003-01       Impact factor: 3.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.